IL17A and myeloid sarcoma: Data from MS patients have shown that IL-17 is increased in the CSF of RRMS patients and correlates with the CSF serum albumin quotient representative of BBB disruption, implying a correlation of IL-17 in BBB disruption and indicating that targeting IL-17 could preserve BBB integrity [43].